Semax: legal status and evidence

Short answer: Semax is not FDA-approved. Since October 30, 2026, a state-licensed pharmacy may compound Semax (free base) for one patient with a prescription under an interim HHS policy, in these forms only: intranasal (nasal spray) only [1], [2]. FDA’s own staff reviewed the evidence and recommended against it [2], [3].

At a glance

Legal status	HHS interim policy: compounding with a patient-specific prescription [1]
Form covered	Semax (free base) [2]
Routes allowed	Intranasal (nasal spray) only [2]
FDA Category 2	September 29, 2023 to April 22, 2026 [2]
FDA staff view	Recommended against adding it to the 503A bulks list [2], [3]
Advisory committee	Voted in favor [2]
Human evidence (FDA review)	Not enough evidence. FDA called the human studies small and poorly described. [3]
Last checked	November 5, 2026

What FDA’s staff found

FDA’s drug center (CDER) reviewed Semax for the uses it was nominated for: cerebral ischemia, migraine and trigeminal neuralgia [3].

• FDA found insufficient evidence that Semax works for the nominated uses. The studies it found were small and gave too few details. [3]
• It found no studies of how the human body absorbs or clears Semax, and insufficient information to describe its safety in people. [3]
• Animal findings raised questions about abuse potential, which FDA said need more study. [3]

Why HHS allowed it anyway

HHS gave three reasons in Appendix B to its policy [2]:

1. Certificates from FDA-registered sources now supply the endotoxin result FDA’s review named as the main gap, plus identity, purity, impurities, residual solvents and the salt form;
2. Use is now documented and counted;
3. The intranasal human record that FDA’s own review compiled covers several hundred people with no reported adverse outcome, and the bleeding and abuse-potential signals have no clinical counterpart in that record.

HHS may revisit the policy if a safety signal or a product quality problem appears, and the policy lasts until FDA decides in a final rule whether to add the peptide to the 503A bulks list [1].

How to get it legally

1. A licensed clinician decides it is right for you and writes a prescription in your name.
2. A state-licensed compounding pharmacy (503A) prepares it from an ingredient made at an FDA-registered facility, with a valid certificate of analysis [1].
3. The label says: “This is a compounded drug product. Not for resale.” It contains only one active ingredient [1].

See how to check a compounding pharmacy and how to read a peptide COA.

What is not known

FDA’s review found too little human data to describe how well Semax works or how safe it is over time [3]. Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed [1]. Talk to a licensed clinician before you use any compounded peptide.

Change log

• November 5, 2026: page created from the HHS policy, Appendix B and FDA’s July 2026 briefing document.